1.Effect of Shenfu Injection on QRS Complex in Patients with Chronic Heart Failure
Qiang PEI ; Xide ZHAO ; Wenfeng SANG
Herald of Medicine 2014;(11):1470-1473
Objective To investigate the relationship among electrocardiogram QRS complex duration,left ventricular ejection fraction( LVEF),N-terminal pro-brain natriuretic peptide( NT-proBNP)and their relation to New York Heart Association (NYHA)functional classification in patients with chronic heart failure(CHF),and observe the intervention effects of Shenfu injection(SFI)on patients with CHF. Methods A total of 72 CHF patients were randomly assigned to treatment group(36 cases)and control group(36 cases). Patients in the control group received standard care,and those in the treatment group received standard care plus 1. 0 mL·kg-1 ·d-1 of SFI in 5% glucose for two weeks. Before and after the treatments,the electrocardiogram QRS complex duration,LVEF,NT-proBNP were measured and NYHA functional classification was evaluated. Results Electrocardiogram QRS complex duration was negatively correlated with LVEF and was positively correlated with NT-proBNP and NYHA functional classification( P〈0. 05 ). After the treatment,the proportion of patients with NYHA classⅠ-Ⅱsignificantly increased and classⅢ-Ⅳsignificantly decreased in both groups. The treatment group was superior to the control group in reinstating cardiac function( P〈0. 05 ). After the treatment,electrocardiogram QRS complex duration and the levels of NT-proBNP were significantly descended and LVEF were significantly ascended in both groups(P〈0. 05). The level of NT-proBNP in the treatment group was significantly lower than in the control group(P〈0. 05),but electrocardiogram QRS complex duration and LVEF did not show significant difference. The prior-and post-treatment difference in electrocardiogram QRS complex duration and LVEF was more obvious in the treatment group than in the control(P〈0. 05). Conclusion The extension of electrocardiogram QRS complex duration is correlated with plasma NT-proBNP elevation and cardiac dysfunction,which can be used as a reference for disease progression or medication efficacy. SFI is effective on CHF of the yang-qi deficiency type.
2.Experimental study on anti-atherosclerosis effects of Guizhi Fuling Capsule
Qiang PEI ; Wenfeng SANG ; Li ZANG ; Shouhua LIU ; Xide ZHAO
International Journal of Traditional Chinese Medicine 2010;32(6):493-495
Objective To observe the anti-atherosclerosis effects of Guizhi Fuling Capsule. Methods 50 healthy SD male rats were randomly divided into 2 groups: normal group (n=12) and AS model group(n=38). The model of experimental AS rats was established by feeding high cholesterol diet and intraperitoneal injecting VitD3. The normal control group was fed by ordinary diet. AS model group was further divided into 3 groups randomly: AS group(n=12), control group (n= 12), and therapy group(n= 12). The therapy group was given Guizhi Fuling Capsule by intragastric administration.The control group was given simvastatin and captopril by intragastric administration. 0.9% NaCl was given to the AS group instead of Guizhi Fuling Capsule. The rats were killed at the 16th weekend, and their aorta arch and breast aorta were observed.Blood fat and serum levels of Endothelin-1 (ET-1), Nitric oxide (NO), high-sensitivity C-reactive protein (hs-CRP) were detected respectively. Immunohistochemistry technology was used for observing the expression of intercellular adhesion molecule- 1 (ICAM- 1 ) in breast aorta. Results The values of ET- 1, NO, hs-CRP and the amount of ICAM- 1 were (142.61 ±25.67)ng/ml, (66.05 ± 8.63) μmol/L, (2.86±0.40)mg/L, (0.29±0.05) in the normal group; (182.38±22.96)ng/ml, (28.70±4.49)μmol/L, (5.60±0.49)mg/L, (0.58±0.06)in the AS group; (154.37±21.11)ng/ml, (45.88±11.36)μmol/L, (3.66±0.34)mg/L, (0.37±0.04)in the control group and (152.13±23.23)ng/ml, (57.67±8.96)μmol/L, (3.70±0.40)mg/L, (0.36±0.04) in the therapy group respectively. The levels of ET-1, NO, hs-CRP and the amount of ICAM-1 have significant difference between the AS group and the normal group(P=2.47E-4, 6.02E-19, 1.11E-12, 2.51E-18). There was also significant difference between the control group and the AS group(P=0.005, 1.59E-14, 1.87E-5, 3.87E-14). The level of NO in the therapy group was higher than that in the control group (P=0.002). The levels of ET-1, hs-CRP and the amount of ICAM-1 did not have significant difference between the therapy group and the control group(P=0.81, 0.81, 0.48) Conclusion Guizhi Fuling Capsule has effects of Anti-atherosclerosis on rats with AS.
3.Antioxidafion functions of Guizhi-Fuling Capsule in rats with atherosclerosis
Xuemei ZHANG ; Xide ZHAO ; Qiang PEI ; Li ZANG
International Journal of Traditional Chinese Medicine 2011;33(9):795-797
Objective To study antioxidation functions effect of Guizhi-Fuling Capsule in rats with atherosclerosis(AS). Methods 50 healthy SD male rats were randomly divided into 2 groups: normal group(n=12), and AS model group (n=36). The model of experimental AS rats was established by high cholesterol diet and intraperitoneal injecting Vit D3. The normal control group was fed by ordinary diet. AS model group was randomly divided into 3 groups: AS group (n= 12), control group (n= 12), therapy group (n=12). Therapy group was given Guizhi-Fuling Capsule (0.24 g/kg · d-1) , control group was given simvastafin (0.86 mg/kg · d-1 ) and captopril(4.3 mg/kg · d-1)by intragastric administration for four weeks. Oxidized-low density lipoprotein (oxLDL),malondialdehyde (MDA), superoxide dismutase(SOD) in serum were detected at the end of therapy. Results Compared with the normal group The oxLDL [ (83.46 ± 19.42)pg/dl], MDA [ (7.38 ±2.46)nmol/ml] in serum were increased significantly(both P<0.01 ), while SOD[ (135.70±23.49)nu/ml] was decreased significantly (P<0.01 )in AS model group. Compared with the model group, the oxLDL[(45.87± 1l.91)pg/di], MDA[ (5.27 ±1.95)nmol/ml] in serum in control group ,the oxLDL[(26.73±9.06)pg/dl], MDA[(4.05±1.83)nmol/ml] in serum in therapy group were lower significandy (all P<0.01 ), and the lowering effect in therapy group was better than that in control group. SOD in serum was higher significantly in the two treatment groups [in control group (185.87±37.36)nu/ml (P<0.01)、 in therapy group (158.65±31.4S) nu/ml (P<0.05) ], and the increasing effect in therapy group was better than that in control group. ConclusionGuizhi-Fuling Capsule has the effects of resisting atherosclerosis to rats with AS. Its mechanisms maybe relate to its antioxidation functions.
4.Combined effect of octreotide and Dachaihu decoction on treatment of se-vere acute pancreatitis
Hui FENG ; Biao WU ; Xide ZHAO ; Baorui GUO
Chinese Journal of Pathophysiology 2016;32(7):1297-1301
[ ABSTRACT] AIM:To investigate the combined effect of octreotide and Dachaihu decoction on the treatment of severe acute pancreatitis (SAP).METHODS:Wistar rats (n=50) were randomly divided into sham group, SAP group, octreotide group, Dachaihu decoction group and combination group.The quantity of ascites was measured.The levels of amylase, alanine aminotransferase and creatinine in the serum were examined.The morphological changes of the pancreatic tissues were observed by HE staining.The activation of NF-κB and IκBαexpression were determined by Western blot.The mRNA expression with ICAM-1 and IL-1 was detected by qPCR.RESULTS: Combined treatment with octreotide and Dachaihu decoction effectively reduced the quantity of ascites and the levels of amylase, alanine aminotransferase and creat-inine in the serum in SAP rats.Moreover, combined treatment significantly inhibited SAP-induced activation of NF-κB and decrease in IκBαprotein expression, accompanied by a decrease in ICAM-1 and IL-1 mRNA expression.CONCLU-SION:Combination of octreotide with Dachaihu decoction effectively attenuates SAP by inhibiting NF-κB signaling pathway and ICAM-1 and IL-1 expression.